Courtney DiNardo, MD, MSCE

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed overcoming insurance barriers to oral AML treatment access.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, shared antiemetic strategies for GI AEs with oral AML regimens.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed ARC initiative data on venetoclax dose modifications in AML.

Courtney D. DiNardo, MD, MSCE; and Michael R. Savona, MD, weigh whether ASCERTAIN-V data make oral HMA therapy the frontline default in AML.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, explained how an all-oral AML regimen impacts infusion center logistics and patient visits.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, discussed how fast oral DEC-C plus venetoclax may replace IV HMA regimens in AML.

Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.